Loading...
Please wait, while we are loading the content...
Similar Documents
Efficacy of bortezomib, cyclophosphamide and dexamethasone in cardiac AL amyloidosis.
| Content Provider | Europe PMC |
|---|---|
| Author | Brennan, Xavier Withers, Barbara Jabbour, Andrew Milliken, Sam Kotlyar, Eugene Fay, Keith Ma, David Muthiah, Kavitha Hamad, Nada Dodds, Anthony Bart, Nikki Keogh, Anne Hayward, Chris Macdonald, Peter Moore, John |
| Abstract | AbstractCardiac light chain (AL) amyloidosis is a condition with a very poor prognosis. We report a retrospective analysis comparing the traditional melphalan and dexamethasone protocol with cyclophosphamide, bortezomib and dexamethasone in late‐stage cardiac AL amyloidosis. The primary end points were overall survival and haematological response. Both regimens provided meaningful responses in this difficult to treat patient group. |
| Related Links | https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC9828809&blobtype=pdf |
| Page Count | 5 |
| ISSN | 14440903 |
| Journal | Internal Medicine Journal [Intern Med J] |
| Volume Number | 52 |
| DOI | 10.1111/imj.15926 |
| PubMed Central reference number | PMC9828809 |
| Issue Number | 10 |
| PubMed reference number | 36266066 |
| e-ISSN | 14455994 |
| Language | English |
| Publisher | John Wiley & Sons Australia, Ltd |
| Publisher Date | 2022-10-01 |
| Publisher Place | Melbourne |
| Access Restriction | Open |
| Rights License | This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. © 2022 The Authors. Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians. |
| Subject Keyword | cardiac amyloidosis AL amyloidosis heart failure myeloma bortezomib |
| Content Type | Text |
| Resource Type | Article |
| Subject | Internal Medicine |
